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Systemic administration of antibiotics is an inherently inefficient method for achiev-
ing high local tissue concentration, because the vascular system distributes antibiotics
uniformly throughout the entire body, only a fraction of the given dose reaches the site
of infection (1). Direct application and local infusion of antibiotics into the surgical wound
has been found to be more effective. However, the rapid absorption of antibiotics from
the wound site reduces the duration of protection against infection, and local infusion is
cumbersome and requires continuous medical attention. A biodegradable dosage form,
which could be implanted at the site of surgical incision to release the drug over an ex-
tended period of time could be such a method. Extensive work has been done using
poly D,L-(lactide-co-glycolide) and its derivatives as biodegradable polymer matrices;
however, very little work was conducted using non-polymeric materials as biodegrad-
able matrices. The implants containing poly D,L-(lactide-co-glycolide), Tween or Span
and tomsulosin hydrochloride were prepared and their release was observed for up to
10 days by Mamun et al. (2). Localized treatment of osteomylitis by 6-week release of
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Biodegradable implants of ciprofloxacin hydrochloride for
post operative site delivery were prepared using glyceryl
monostearate and different concentrations of polyethyl-
ene glycol (PEG 6000), glycerol and Tween 80 as erosion
enhancers by compression and molding technique. For-
mulations were subjected to in vitro drug release by the
USP dissolution method, while promising formulations
were subjected to in vitro drug release by the agar gel
method and also to stability studies. It was observed that
glyceryl monostearate formed hydrophobic matrix and
delayed the drug delivery. Antibiotic release profile was
controlled by using different combinations of erosion en-
hancers. The formulation prepared by the compression
method showed more delayed release compared to for-
mulations prepared by the molding method.
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ciprofloxacin from implants using poly (D,L-lactide-co-glycolide) (50:50) was reported
by Ramchandani et al. (3). A biodegradable long-acting contraceptive capsule-type im-
plant was developed using biodegradable polyester, polycaprolactone as the principle
matrix and a water-leachable polyether, Pluronic F68, as drug releasing enhancer (4). Le-
vonorgestrel containing capsules showed an average levonorgestrel release rate of 7.0 mg
per day per cm length for a period of 2 years in rats. Baxter Healthcare Corp. (USA) has
recently introduced a gentamicin implant using biodegradable polymers which may re-
duce incidences of surgical site infections and postoperative cast and complications (5).
Guse et al. (6) studied mass transport mechanism involved in the control of drug re-
lease from a lipid-based implant using different types of triglyceride (glyceryl trilaurate,
glyceryl trimyristate, glyceryl tripalmitate and glyceryl tristearate) based cylinders which
were prepared by the compression technique. Granules of glyceryl monostearate, polyethy-
lene glycol (PEG 6000) and Tween 80 were mixed with the drug and compressed to form
pellets, and then dry coated or compressed with glyceryl monostearate to form implant
(7). After initial delay these multilayered implants disintegrate and the compressed mix-
ture of granules containing glyceryl monostearate, polyethylene glycol, Tween 80 and pow-
dered drug are exposed to the dissolution media. This may lead to a pulsatile drug delive-
ry system. To provide a sustained-release drug delivery system the drug might be dis-
persed in the molten mass of glyceryl monostearate containing a release rate modifier.
In the present study biodegradable sustained-release implants for post operative drug
delivery were prepared by dispersing ciprofloxacin hydrochloride in a molten mass of
glyceryl monostearate as the biodegradable hydrophobic matrix having different con-
centrations of erosion enhancers such as PEG 6000, glycerol and Tween 80. To observe
the variation in the drug release pattern, the release profile of the compressed formula-
tion was compared with the molded formulation having the same composition and size.
EXPERIMENTAL
Materials
Ciprofloxacin hydrochloride was a gift sample from Adroit Pharmaceuticals Pvt. Ltd.
(India), polyethylene glycol, Tween 80, glycerol, agar and potassium dihydrogen phos-
phate were purchased from Adroit Pharmaceuticals Pvt. Ltd. Glyceryl monostearate was
supplied by Suyog Chemicals Pvt. Ltd. (India) and all other chemicals used were of labo-
ratory reagents/analytical reagents grade.
Preparation of antibiotic loaded implants
Compression technique. – Glyceryl monostearate, PEG 6000 and glycerol or Tween 80
in specified quantities (Table I) were heated to 70 °C on a water bath under stirring with
a glass rod. The weighed quantity of the drug was dispersed uniformly just before the
mass solidified. The solidified blend was stored in freezer for 1 h, the hard mass was
ground to fine powder and passed through a sieve (aperture 0.42 mm). The granules
were compressed on a rotary compression machine, punch size 8 mm (flat), to form tablet
shaped pellets. Different formulations were prepared using various glycerol or Tween 80
concentrations.
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Molding technique. – The molten mass and the various formulations were prepared
(Table 1) as above, except that the molten mass was drawn up into a 10 mL-syringe and
injected into a cylindrical stainless steel mould of 8 mm diameter. The mould was al-
lowed to cool and each cylindrical pellet was cut into 3-mm long pieces equivalent to
the thickness of pellets prepared by the compression technique, to make the same size
pellets by both techniques.
In vitro evaluation
The release of ciprofloxacin was studied by USP (8) (Disso 2000, paddle method at
50 rpm) at 37 °C in 900 mL of pH 7.4 (0.1 mol L-1) phosphate buffer. Samples were fil-
tered and analyzed spectrophotometrically at 276 nm (Shimadzu 1601, Japan).
Gel simulating in vitro implantation (gel method)
In vitro release was followed by placing the pellet implant in agar gel simulating
subcutaneous tissue conditions with respect to viscosity and water content (9). Agar crys-
tals were dissolved in boiling 0.1 mol L–1 phosphate buffer pH 7.4, to prepare 1.5 % an
agar solution, which was poured into a Petri dish and left to congeal. A hole (8 mm) was
drilled in the center of the agar plate with a cork borer and the pellet/implant was placed
in the hole. Sufficient quantity of hot (50-60 °C) agar solution was poured on the top to
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Table I. Formulations of compressed and molded implants using erosion enhancers
Sample Formulation
Ingredient (%)
Drug GMS PEG 6000 Tween 80 Glycerol
Compressed
1 C1 20.0 40.0 40.0 0.0 0.0
2 C2 20.0 40.0 37.5 2.5 0.0
3 C3 20.0 40.0 35.0 5.0 0.0
4 C4 20.0 40.0 32.5 7.5 0.0
5 C5 20.0 40.0 37.5 0.0 2.5
6 C6 20.0 40.0 35.0 0.0 5.0
7 C7 20.0 40.0 32.5 0.0 7.5
Molded
8 M1 20.0 40.0 40.0 0.0 0.0
9 M2 20.0 40.0 35.0 5.0 0.0
10 M3 20.0 40.0 25.0 15.0 0.0
11 M4 20.0 40.0 10.0 30.0 0.0
12 M5 20.0 40.0 10.0 0.0 30.0
13 M6 20.0 40.0 10.0 15.0 15.0
GMS – glyceryl monostearate
PEG 6000 – polyethylene glycol 6000
cover the implants and left to congeal. The plate was covered and placed in the oven (37
°C). Several agar plates implanted with ciprofloxacin devices were prepared at the same
time and the samples were collected at 6, 24, 48, 72, 96 h. At each sampling time, one
plate was removed from the oven. The plate was divided into four sampling zones and
three samples were removed from each zone using a size 4 cork borer (8 mm in diame-
ter). The samples were accurately weighed and dissolved in boiling buffer containing 25
% NaCl. The solution was cooled in an ice bath to precipitate the agar.
Stability studies
Formulations C3 and M2 (both containing 5.0 % of Tween 80, six of each), were
wrapped in aluminum foil, sealed and kept for stability studies as per ICH guidelines
(10), under conditions 40 ± 2 °C / 75 ± 5 % RH. Every month, one sample from each for-
mulation was withdrawn and estimated for drug concentration. Weighted formulation
was crushed and dissolved in 0.1 m mol L–1 HCl under stirring for 2 h and the drug con-
centration was calculated.
RESULTS AND DISCUSSION
Formulation prepared by the compression technique C1 (containing 40.0 % PEG 6000)
showed up to 59.0 % of drug release in 36 h. Formulation C6 containing 5.0 % glycerol
showed 93.8 % of drug release in 36 h compared to 75.2 % from C3 containing the same
concentration of Tween 80. Higher drug release from implants containing erosion enhan-
cers may be due to the solubility of erosion enhancers leading to higher porosity of the
formulation. Agitation also helps the formulation to disintegrate and provide a larger
surface area to enhance drug release. In the case of formulations containing glycerol, high-
er percentage of drug release was observed because of the higher hydrophilicity of glyc-
erol compared to the formulations containing Tween 80 (Fig. 1a). Increasing the concen-
tration of Tween 80 (C4) or glycerol (C7) from 5.0 to 7.5 % led to soft and sticky formula-
tions causing difficulty in compression; hence these were not used in further studies.
Uncompressed formulations prepared by the molding technique showed faster disso-
lution due to higher erosion during dissolution. Formulation M1 (containing 40.0 % PEG
6000) showed 73.5 % drug release, while the formulation containing 5.0 % of Tween 80
(M2) showed higher drug release of 81.0 % in 36 h. Formulation M6 containing equal
proportions of glycerol and Tween 80 (15.0 % each) showed intermediate release com-
pared to formulations M4 and M5 containing 30.0 % of either Tween 80 or glycerol (Fig. 1b).
Delayed drug release from compressed formulations was observed compared to molded
formulations, which could be due to the compactness in the dosage form leading to a re-
duction in porosity, lower erosion and penetration of dissolution fluid into the dosage
form.
In vitro drug release kinetics of the formulations prepared by the compression tech-
nique (C3) and molding technique (M2) were analyzed by PCP Disso V-3 software (Poona
College of Pharmacy, Pune, India).
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Considering the release pattern from the formulations C3 (containing 5.0 % of Tween
80) prepared by the compression technique and similar formulation M2 (containing iden-
tical percentage of Tween 80) prepared by the molding technique were selected for evalu-
ation by the gel simulation method.
Release of ciprofloxacin hydrochloride from glyceryl monostearate matrixes in the
gel method was conducted in order to stimulate the in vivo implantation conditions, un-
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Fig. 1. Comparative in vitro ciprofloxacin hydrochloride release profiles from formulations prepa-
red by: a) compression method, b) molding method, c) C3 and M2 (both containing 5.0 % Tween 80)
from agar gel. For composition see Table I. Each point denotes mean ± SD, n = 3.
der which the implanted matrixes are surrounded by tissues rather than by aqueous so-
lution. Drug release from the insoluble matrix is generally achieved by penetration of
the release medium into the matrix and dissolution of the drug, followed by diffusion of
the drug solution through the channels and pores of the matrix.
The drug release from formulations C3 and M2 (both containing 5.0 % Tween 80) in
agar gel simulating subcutaneous tissue resulted in significant difference in the drug re-
lease pattern compared to the release pattern in dissolution studies. Pellets prepared by
the molding technique using 5.0 % Tween 80 (M2) showed 65.5 % higher drug release as
compared to the pellets prepared by the compression technique, 32.5 % in 96 h (Fig. 1c).
In the agar gel method, drug release taken place by diffusion; a layer close to the im-
plant has higher drug concentration and is inversely proportional to the distance. Per-
centage diffusion of the drug in the absence of any agitation is also dependent on the
solubility of the drug in the aqueous phase.
The commonly adopted model for understanding the release behaviour of the drug
from an inplant is the Korsmeyer-Peppas equation. The release exponent n is releated to
the drug release mechanism; the values of 0.6491 and 0.6022 for C3 and M2 (11) resp. in-
dicate anomalous transport (diffusion coupled with the erosion mechanism). R2 values
of linear regression for the Higuchi plot were 0.9852 and 0.9786 for C3 and M2, resp.,
indicating that the data fit best the Higuchi model.
The values of n in the agar gel method were 0.2441 and 0.4188 for C3 and M2, resp.,
indicating Fickian transport (diffusion mechanism). The R2 values for the Higuchi plot
were 0.9649 and 0.9885 for C3 and M2, resp. This system was also best presented by the
Higuchi model.
In accelerated stability studies, both formulations C3 and M2, having the same com-
position but differing in the preparation technique, remained stable enough over the de-
signated period under accelerated conditions (40 ± 2 °C/75 ± 5 % RH). The initial drug
concentration remained constant for a month and dropped by 0.6 and 0.4 %, resp. after 3
months and by 1.5 and 1.3 %, resp. after 6 months.
CONCLUSIONS
On the basis of the results obtained, it can be concluded that glyceryl monostearate
forms the hydrophobic matrix for a controlled drug delivery system. Formulations pre-
pared by the compression or molding technique can be implanted subcutaneously at the
site of surgery to prevent postoperative infection. The dissolution profile of formulations
can be controlled by the use of an erosion enhancer and by the preparation technique. In
subcutaneous implantation, the release pattern is dependent on the preparation techni-
que as well as on the solubility of the drug in the aqueous phase.
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S A @ E T A K
Priprava i vrednovanje biorazgradljivih implantata s kontroliranim osloba|anjem
za postoperativnu primjenu
VIJAY MATHUR, RAJESH MUDNAIK, LAXMIKANT BARDE, ARGHYA ROY, UMESH SHIVHARE i KISHORE BHUSARI
Biorazgradljivi implantati ciprofloksacin hidroklorida za postoperativnu primjenu
pripravljeni su pomo}u gliceril monostearata (GMS) i razli~itih koncentracija polietilen
glikola (PEG 6000), glicerola i Tween 80 kao promotora erozije metodom kompresije i
lijevanja. Osloba|anje ljekovite tvari iz pripravaka pra}eno je in vitro prema USP metodi.
Pripravci koji su dali dobre rezultate ispitani su i in vitro metodom s agarom te su pod-
vrgnuti testovima stabilnosti. Primije}eno je da gliceril monostearat tvori hidrofobni ma-
triks i usporava osloba|anje lijeka. Koriste}i razli~ite kombinacije promotora erozije posti-
gnuto je kontrolirano osloba|anje antibiotika. Osloba|anje iz implantata dobivenih me-
todom kompresije sporije je od implantata dobivenih metodom lijevanja.
Klju~ne rije~i: biorazgradljivi implantati antibiotika, gliceril monostearat, kontrolirano osloba|anje,
mjesto isporuke, promotor erozije
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